

# Cancer Immunology

## RESEARCH PROGRAM

**Friday, October 9, 2020**

12:00 pm

Virtual Seminar via Zoom

***“SBT6050: A HER2-Directed TLR8 Agonist  
Antibody Conjugate for Potent, Tumor-  
Localized Activation of Myeloid Cells”***

**Valerie Odegard, PhD**

Chief Scientific Officer  
Silverback Therapeutics